The estimated Net Worth of Thomas J. Schall is at least $137 million dollars as of 4 August 2022. Thomas Schall owns over 130,000 units of ChemoCentryx Inc stock worth over $131,189,070 and over the last 13 years he sold CCXI stock worth over $1,975,208. In addition, he makes $3,341,860 as Chairman of the Board, President et Chief Executive Officer at ChemoCentryx Inc.
Thomas has made over 49 trades of the ChemoCentryx Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 130,000 units of CCXI stock worth $1,856,400 on 4 August 2022.
The largest trade he's ever made was exercising 279,166 units of ChemoCentryx Inc stock on 26 November 2019 worth over $1,758,746. On average, Thomas trades about 40,615 units every 59 days since 2012. As of 4 August 2022 he still owns at least 2,523,352 units of ChemoCentryx Inc stock.
You can see the complete history of Thomas Schall stock trades at the bottom of the page.
Dr. Thomas J. Schall Ph.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Thomas J. Schall, Ph.D. is the founder of our company and has served as our President, Chief Executive Officer and Director since we commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to March 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall’s laboratories have been responsible for the discovery or co-discovery of almost one-third of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University. Schall is qualified to serve on our board of directors because of his extensive executive leadership experience, many years of service as one of our directors and our President and Chief Executive Officer and extensive scientific expertise and knowledge of the chemokine system.
As the Chairman of the Board, President et Chief Executive Officer of ChemoCentryx Inc, the total compensation of Thomas Schall at ChemoCentryx Inc is $3,341,860. There are no executives at ChemoCentryx Inc getting paid more.
Thomas Schall is 60, he's been the Chairman of the Board, President et Chief Executive Officer of ChemoCentryx Inc since 2012. There are 5 older and 7 younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 835 INDUSTRIAL ROAD, SUITE 600, SAN CARLOS, CA, 94070.
Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta et (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ChemoCentryx Inc executives and other stock owners filed with the SEC include: